RxDoctor Payments DataLook up a doctor →

Carol Monroe, NP

Nurse Practitioner · Neosho, MONPI 1700835345

Payments from drug & device makers

$11,513in general payments, 2019–2025

Across 687 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Novo Nordisk$854
  • Lilly USA, LLC$845
  • Johnson & Johnson$747
  • Amgen$592
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$11,500100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,513 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$187
Medicare patients
11
Services billed
15

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$51,119
EliquisApixaban35$39,735
JardianceEmpagliflozin41$34,259
XareltoRivaroxaban28$29,453
JanuviaSitagliptin Phosphate11$13,259
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$8,214
Tiotropium Bromide12$5,737
SymbicortBudesonide/Formoterol Fumarate21$5,423
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,560
Solifenacin Succinate16$2,525
Gabapentin215$2,499
Dexlansoprazole DrDexlansoprazole11$1,790
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,723
Omeprazole137$1,414
Potassium Chloride54$1,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$854$51,11945 claims
PfizerEliquis$503$39,73535 claims
Boehringer IngelheimJardiance$363$34,25941 claims
Johnson & JohnsonXarelto$747$29,45328 claims
MerckJanuvia$92$13,25911 claims
AstraZenecaSymbicort$1,928$5,42321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Neosho

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →